Use access key #2 to skip to page content.

portefeuille (99.60)

biotech siRNA

Recs

1

March 18, 2010 – Comments (8)

SIRNA was the ticker symbol of Sirna Therapeutics.

Merck Closes $1.1B Sirna Acquisition After RNAi Shop Tentatively Settles Three Lawsuits

Merck's Big Play in RNA

Merck's risky bet on a little biotech

Merck’s Alan Sachs, on RNAi’s Big Challenge: Delivery, Delivery, Delivery

Merck's Sirna Acquisition Adds the Kind of Value Wall Street Doesn't See

Alnylam, RXi On Collision Course Over Intellectual Property From Massachusetts Life Sciences Initiative

Alnylam and RXi: A match made in heaven?

Tekmira shares surge on Pfizer collaboration

Tekmira Pharmaceuticals Provides Corporate Update and Reports 2009 Audited Results

for the hobby scientists ...

RNAi

Targeted mRNA degradation by double-stranded RNA in vitro

Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells

zzlangerhans made an "outperform" call on RXII on 03/12/10. So did I on 03/16/10 having looked at it (more of a "casual glance").

---------------

#998) On February 12, 2010 at 9:37 PM, portefeuille (99.97) wrote: ALNY - 17.48 - outperform

#1064) On March 15, 2010 at 8:30 PM, portefeuille (99.97) wrote: RXII - 6.59 - outperform

---------------

(from here)

 

some charts (CYTR is still a "major holder" of RXII shares).



enlarge

 



enlarge

 



enlarge

 



enlarge

8 Comments – Post Your Own

#1) On March 18, 2010 at 10:20 AM, portefeuille (99.60) wrote:

#88) On March 16, 2010 at 2:30 PM, portefeuille (99.97) wrote: TKM:CN - 0.83 (0.84 CAD) - outperform (high risk!)

(from here)

 

#1067) On March 18, 2010 at 10:19 AM, portefeuille (99.97) wrote: TKM:CN - 0.89 (0.90 CAD) - outperform

(from here)

 

Report this comment
#2) On March 18, 2010 at 10:42 AM, gonelong (34.92) wrote:

Do you run any kind of technical screen?

It seems like a number of the companies you follow are 50+ RSI, rising volume, EMA crosses of one sort or another, etc.

Just curious.

GL

Report this comment
#3) On March 18, 2010 at 10:50 AM, portefeuille (99.60) wrote:

no, none of that. volume is usually higher than average on the days I make the calls when it is more or less an "event driven" call.

Report this comment
#4) On March 18, 2010 at 3:59 PM, portefeuille (99.60) wrote:

SIRNA was the ticker symbol of Sirna Therapeutics.

RNAI was the ticker symbol of Sirna Therapeutics.

Report this comment
#5) On March 21, 2010 at 3:53 PM, portefeuille (99.60) wrote:

Cancer genes silenced in humans

Nanotech robots deliver gene therapy through blood

Caltech-led team provides proof in humans of RNA interference using targeted nanoparticles

Research provides proof in humans of RNA interference using targeted nanoparticles

 

Report this comment
#6) On March 21, 2010 at 4:00 PM, portefeuille (99.60) wrote:

---------------

Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles

Mark E. Davis1, Jonathan E. Zuckerman1, Chung Hang J. Choi1, David Seligson2,3, Anthony Tolcher5, Christopher A. Alabi1,8, Yun Yen6, Jeremy D. Heidel7 & Antoni Ribas2,4

...

Therapeutics that are designed to engage RNA interference (RNAi) pathways have the potential to provide new, major ways of imparting therapy to patients1, 2. Long, double-stranded RNAs were first shown to mediate RNAi in Caenorhabditis elegans3, and the potential use of RNAi for human therapy has been demonstrated by the finding that small interfering RNAs (siRNAs; approximately 21-base-pair double-stranded RNA) can elicit RNAi in mammalian cells without producing an interferon response4. We are at present conducting the first in-human phase I clinical trial involving the systemic administration of siRNA to patients with solid cancers using a targeted, nanoparticle delivery system. Here we provide evidence of inducing an RNAi mechanism of action in a human from the delivered siRNA. Tumour biopsies from melanoma patients obtained after treatment show the presence of intracellularly localized nanoparticles in amounts that correlate with dose levels of the nanoparticles administered (this is, to our knowledge, a first for systemically delivered nanoparticles of any kind). Furthermore, a reduction was found in both the specific messenger RNA (M2 subunit of ribonucleotide reductase (RRM2)) and the protein (RRM2) levels when compared to pre-dosing tissue. Most notably, we detect the presence of an mRNA fragment that demonstrates that siRNA-mediated mRNA cleavage occurs specifically at the site predicted for an RNAi mechanism from a patient who received the highest dose of the nanoparticles. Together, these data demonstrate that siRNA administered systemically to a human can produce a specific gene inhibition (reduction in mRNA and protein) by an RNAi mechanism of action.

...

---------------

Report this comment
#7) On March 21, 2010 at 4:04 PM, portefeuille (99.60) wrote:

good old Caenorhabditis elegans, hehe ...

Report this comment
#8) On March 21, 2010 at 8:00 PM, portefeuille (99.60) wrote:

CALAA-01 Results Indicate RNAi Therapeutics to Revolutionize Solid Cancer Treatment

Report this comment

Featured Broker Partners


Advertisement